Skip to main content
. Author manuscript; available in PMC: 2018 Mar 15.
Published in final edited form as: Curr Oncol Rep. 2015 Apr;17(4):15. doi: 10.1007/s11912-015-0438-0

Figure 2. Genomic Alterations in 128 Potentially Clinically Relevant Genes in 962 TCGA Breast Cancer Samples.

Figure 2

Genomic profiling efforts may identify genomic altertaions that can be used for clinical decision making, such as the choice of therapeutic agent or clinical trials. Interrogating 962 breast cancer samples that have been sequenced as part of the TCGA project (available at cbioportal.org) for genomic alterations in 128 potentially clinically relevant genes56 reveals alterations in numerous genes across the cohort, ranging in frequency from >40% (PIK3CA) to <5% (AKT1, MAP2K2). Examples of therapeutic agents that target several of these genes are highlighted.